The value of HDL genetics

Purpose of review To review studies on hereditary disorders of high-density lipoprotein (HDL) metabolism and studies on HDL genetics in mice, which have both provided valuable insight into the pathways of this intriguing lipoprotein and moreover revealed targets to raise HDLc to reduce atherosclerosis. Recent findings To date, as many as 11 genes are considered key players in the synthesis, maturation, conversion and/or catabolism of HDL. Five of these genes have been identified in humans, APOA1, LCAT, ABCA1, LIPC, and CETP, whereas the other six genes have been identified in mice, SCARB1, ABCG1, ATPB5, PLTP, LIPG and APOM. Genetic association studies are as yet the best line of evidence of the roles of the ‘murine genes’ in human HDL pathways. In addition to recent genetic association studies, a third section describes exciting news on six newly proposed HDL genes VNN1, GALNT2, MMAB/MVK, CTα, BMP-1 and SIRT1. Summary This review provides a summary of the current literature on the genetics of HDL. New information from this research area may assist us in obtaining a better understanding of HDL biology and identifying novel pharmacological targets.

[1]  A. Tall,et al.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. , 2007, The Journal of clinical investigation.

[2]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[3]  Kenichi Yoshida,et al.  Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.C200010-JLR200 , 2002, Journal of Lipid Research.

[4]  D. Thomas,et al.  Are We Ready for Genome-wide Association Studies? , 2006, Cancer Epidemiology Biomarkers & Prevention.

[5]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[6]  B. McManus,et al.  Increased ABCA1 activity protects against atherosclerosis. , 2002, The Journal of clinical investigation.

[7]  P. Elliott,et al.  Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides , 2008, Nature Genetics.

[8]  M. Lambert,et al.  Outcome of individuals with low-moderate methylmalonic aciduria detected through a neonatal screening program. , 1999, The Journal of pediatrics.

[9]  B. Nordestgaard,et al.  Genetic Variation in ABCA1 Predicts Ischemic Heart Disease in the General Population , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Rubin,et al.  Lower Plasma Levels and Accelerated Clearance of High Density Lipoprotein (HDL) and Non-HDL Cholesterol in Scavenger Receptor Class B Type I Transgenic Mice* , 1999, The Journal of Biological Chemistry.

[11]  C. Fielding,et al.  Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. , 2007, Biochemistry.

[12]  Sungshin Y. Choi,et al.  Endothelial Lipase Modulates Susceptibility to Atherosclerosis in Apolipoprotein-E-deficient Mice* , 2004, Journal of Biological Chemistry.

[13]  F. Grosveld,et al.  Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[14]  B. Dahlbäck,et al.  Isolation and characterization of human apolipoprotein M-containing lipoproteins Published, JLR Papers in Press, May 8, 2006. , 2006, Journal of Lipid Research.

[15]  M. Reilly,et al.  Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo , 2003, Circulation.

[16]  G. Assmann,et al.  Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins. , 1978, Biochimica et biophysica acta.

[17]  Yannick Hamon,et al.  ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. , 2000, Nature Cell Biology.

[18]  J. Auwerx,et al.  Sirtuin functions in health and disease. , 2007, Molecular endocrinology.

[19]  A. Tall,et al.  Decreased Atherosclerosis in Heterozygous Low Density Lipoprotein Receptor-deficient Mice Expressing the Scavenger Receptor BI Transgene* , 1999, The Journal of Biological Chemistry.

[20]  Michael Miller,et al.  Genetics of HDL regulation in humans , 2003, Current opinion in lipidology.

[21]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[22]  A. Brownlie,et al.  A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. , 2004, Journal of the American College of Cardiology.

[23]  B. Paigen,et al.  Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio , 1996, International journal of clinical & laboratory research.

[24]  Olle Melander,et al.  Polymorphisms associated with cholesterol and risk of cardiovascular events. , 2008, The New England journal of medicine.

[25]  Gerd Schmitz,et al.  ABCA1: regulation, trafficking and association with heteromeric proteins , 2002, Annals of medicine.

[26]  K. Kotani,et al.  The common -55 C/T polymorphism in the promoter region of the uncoupling protein 3 gene reduces prevalence of obesity and elevates serum high-density lipoprotein cholesterol levels in the general Japanese population. , 2008, Metabolism: clinical and experimental.

[27]  K. Roomp,et al.  ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels , 2002, Clinical genetics.

[28]  M. Freeman,et al.  Genetic Etiology of Isolated Low HDL Syndrome: Incidence and Heterogeneity of Efflux Defects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[29]  L. Solberg,et al.  Mice overexpressing human lecithin: cholesterol acvltransferase are not protected against diet‐induced atherosclerosis , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  J. van der Meer,et al.  Effect of inflammatory attacks in the classical type hyper‐IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response , 2004, Journal of internal medicine.

[31]  F. Kuipers,et al.  Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL , 2001 .

[32]  F. Kuipers,et al.  Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. , 2001, The Journal of clinical investigation.

[33]  Sungshin Y. Choi,et al.  Endothelial lipase is a major determinant of HDL level. , 2003, The Journal of clinical investigation.

[34]  R. F. Hoyt,et al.  Targeted Disruption of the Mouse Lecithin:Cholesterol Acyltransferase (LCAT) Gene , 1997, The Journal of Biological Chemistry.

[35]  D. Rader,et al.  A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.

[36]  M. Mackness,et al.  Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? , 2004, Free radical biology & medicine.

[37]  T. Hudson,et al.  Identification of the gene responsible for the cblB complementation group of vitamin B12-dependent methylmalonic aciduria. , 2002, Human molecular genetics.

[38]  A. von Eckardstein,et al.  Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. , 1991, The Journal of clinical investigation.

[39]  S. Squazzo,et al.  Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[41]  Paul T. Tarr,et al.  ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. , 2005, Cell metabolism.

[42]  I. Kullo,et al.  Genetic determinants of HDL: monogenic disorders and contributions to variation , 2007, Current opinion in cardiology.

[43]  W. Fung-Leung,et al.  Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  O. Francone,et al.  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001, The Journal of clinical investigation.

[45]  D. Rader Illuminating HDL--is it still a viable therapeutic target? , 2007, The New England journal of medicine.

[46]  H. Brewer,et al.  Study of ABCA1 function in transgenic mice. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[47]  M. Hayden,et al.  Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. , 2000, The Journal of clinical investigation.

[48]  E. Goode,et al.  Heritability of Longitudinal Measures of Body Mass Index and Lipid and Lipoprotein Levels in Aging Twins , 2007, Twin Research and Human Genetics.

[49]  T. Hudson,et al.  Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. , 2007, American journal of human genetics.

[50]  A. Rigotti,et al.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  C. Heng,et al.  ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore , 2003, Human Genetics.

[52]  S. Vilaró,et al.  The role of O‐linked sugars in determining the very low density lipoprotein receptor stability or release from the cell , 1999, FEBS letters.

[53]  Xavier Collet,et al.  Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis , 2003, Nature.

[54]  R. Krauss,et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.

[55]  A. Tall CETP inhibitors to increase HDL cholesterol levels. , 2007, The New England journal of medicine.

[56]  R. Hegele,et al.  Genetic determinants of plasma lipoproteins , 2007, Nature Clinical Practice Cardiovascular Medicine.

[57]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[58]  G. Francis,et al.  Hepatic CTP:Phosphocholine Cytidylyltransferase-α Is a Critical Predictor of Plasma High Density Lipoprotein and Very Low Density Lipoprotein* , 2008, Journal of Biological Chemistry.

[59]  J. Jukema,et al.  CETP gene variation: relation to lipid parameters and cardiovascular risk , 2004, Current opinion in lipidology.

[60]  D. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.

[61]  T. Langmann,et al.  Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice , 2000, Nature Genetics.

[62]  D. Russell,et al.  Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. , 1985, Annual review of cell biology.

[63]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[64]  Mark I McCarthy,et al.  What makes a good genetic association study? , 2005, The Lancet.

[65]  S. Meaney,et al.  Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism. , 2007, Biochemical and biophysical research communications.

[66]  M. Gültepe,et al.  Altered red cell membrane compositions related to functional vitamin B12 deficiency manifested by elevated urine methylmalonic acid concentrations in patients with schizophrenia , 2008, Annals of clinical biochemistry.

[67]  M. N. Poy,et al.  Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis , 2005, Nature Medicine.

[68]  P. Linsel-Nitschke,et al.  HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[69]  G. Assmann,et al.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. , 1997, Journal of lipid research.

[70]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[71]  John L Hopper,et al.  Population-based family studies in genetic epidemiology , 2005, The Lancet.

[72]  K. Kotani,et al.  Relationship between A-3826G polymorphism in the promoter of the uncoupling protein-1 gene and high-density lipoprotein cholesterol in Japanese individuals: a cross-sectional study. , 2008, Archives of medical research.

[73]  M. Permutt,et al.  Variants in the CD 36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol , 2008 .

[74]  A. von Eckardstein,et al.  Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. , 2006, Biochimica et biophysica acta.

[75]  M. Permutt,et al.  Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. , 2008, Human molecular genetics.

[76]  A. Tall,et al.  Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.

[77]  Eric Boerwinkle,et al.  Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL , 2007, Nature Genetics.

[78]  A. Tall,et al.  ATP-binding cassette transporters G 1 and G 4 mediate cellular cholesterol efflux to high-density lipoproteins , 2004 .

[79]  Sekar Kathiresan,et al.  Defining the spectrum of alleles that contribute to blood lipid concentrations in humans , 2008, Current opinion in lipidology.

[80]  G. Hoffmann,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .

[81]  E. Boerwinkle,et al.  The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability , 2006, Journal of Molecular Medicine.

[82]  L. Guarente,et al.  SIRT1 deacetylates and positively regulates the nuclear receptor LXR. , 2007, Molecular cell.

[83]  H. Brewer,et al.  ABCA1 Overexpression in the Liver of LDLr-KO Mice Leads to Accumulation of Pro-atherogenic Lipoproteins and Enhanced Atherosclerosis* , 2006, Journal of Biological Chemistry.

[84]  S. Deeb,et al.  A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. , 1990, American journal of human genetics.

[85]  T. Arinami,et al.  Relationship between serum HDL-C levels and common genetic variants of the endothelial lipase gene in Japanese school-aged children , 2003, Human Genetics.

[86]  K. Lunetta Genetic Association Studies , 2008, Circulation.

[87]  T. Gotoda [Lecithin-cholesterol acyltransferase deficiency and fish eye disease]. , 1998, Ryoikibetsu shokogun shirizu.

[88]  B. Porse,et al.  Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice* , 2008, Journal of Biological Chemistry.

[89]  D. Strachan,et al.  LDL-cholesterol concentrations: a genome-wide association study , 2008, The Lancet.

[90]  D. Sviridov,et al.  Genetic factors affecting HDL levels, structure, metabolism and function , 2007, Current opinion in lipidology.

[91]  J. Jukema,et al.  Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels , 2006, Clinical genetics.

[92]  P. Wilson,et al.  Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. , 2003, The Journal of clinical endocrinology and metabolism.

[93]  S. Choi,et al.  Association of UCP2 and UCP3 gene polymorphisms with serum high-density lipoprotein cholesterol among Korean women. , 2007, Metabolism: clinical and experimental.

[94]  Nicole A. Leal,et al.  Identification of the Human and Bovine ATP:Cob(I)alamin Adenosyltransferase cDNAs Based on Complementation of a Bacterial Mutant* , 2003, The Journal of Biological Chemistry.

[95]  J. Witteman,et al.  The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. , 2004, The Journal of clinical endocrinology and metabolism.

[96]  Peter Tontonoz,et al.  Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. , 2006, Annual review of medicine.

[97]  J. Carlquist,et al.  Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis , 2007, Current opinion in cardiology.

[98]  Colin Berry,et al.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.

[99]  R. Hegele,et al.  Is raising HDL a futile strategy for atheroprotection? , 2008, Nature Reviews Drug Discovery.

[100]  A. Tall,et al.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. Dixon,et al.  Analysis of a missense variant of the human N-formyl peptide receptor that is associated with agonist-independent β-arrestin association and indices of inflammation , 2007, The Pharmacogenomics Journal.

[102]  J. Engert,et al.  Genetics of high-density lipoproteins , 2006, Current opinion in cardiology.

[103]  J. van der Meer,et al.  Hyper-Immunoglobulin A in the Hyperimmunoglobulinemia D Syndrome , 2001, Clinical Diagnostic Laboratory Immunology.

[104]  J. Parks,et al.  Lecithin:Cholesterol Acyltransferase Deficiency Increases Atherosclerosis in the Low Density Lipoprotein Receptor and Apolipoprotein E Knockout Mice* , 2002, The Journal of Biological Chemistry.

[105]  P. A. Peterson,et al.  Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. , 2000, The American journal of pathology.

[106]  A. Hofman,et al.  Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. , 2007, The Journal of clinical endocrinology and metabolism.

[107]  L. Almasy,et al.  Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes , 2007, Nature Genetics.

[108]  P J Talmud,et al.  Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects , 2005, Circulation.

[109]  Jonathan C. Cohen,et al.  Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. , 2007, American journal of human genetics.

[110]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[111]  Xavier Collet,et al.  Site‐specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion , 1995, Protein science : a publication of the Protein Society.

[112]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[113]  D. Stengel,et al.  Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice: LCAT Gene Transfer Decreases Atherosclerosis , 2003, Circulation.

[114]  D. Rader,et al.  Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[115]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[116]  P. Barter,et al.  High-density lipoproteins as therapeutic targets , 2005, Current opinion in lipidology.

[117]  M. Krieger,et al.  Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice , 2002, Circulation research.

[118]  A. Zwinderman,et al.  Compromised LCAT Function Is Associated With Increased Atherosclerosis , 2005, Circulation.